Skip to Content

'
Jason Westin

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

My research focus is on improving therapy and outcomes for patients with lymphoma.

 My specific research interests include:

  1. Diffuse Large B-cell Lymphoma
  2. Development of systems to identify novel, optimal therapeutic combinations for individual patients
  3. Drug synergy, additivity, and antagonism
  4. Scale free networks and their role in cancer therapy
  5. Development of highly sensitive disease monitoring methods

 

Education & Training

Degree-Granting Education

2015 University of Texas Graduate School of Biomedical Sciences, Houston, TX, MS, Clinical and Translational Sciences
2002 University of Florida, Gainesville, FL, MD, elected to AOA, Medicine
1998 University of Florida, Gainesville, FL, BS, Cum Laude, Microbiology

Postgraduate Training

6/2011-6/2012 Research Fellowship, Advanced Scholar - Lymphoma, University of Texas MD Anderson Cancer Center, Houston, TX
7/2010-6/2011 Chief Fellow, M.D. Anderson Cancer Center, Houston, TX
7/2008-6/2011 Clinical Fellowship, Hematology/Oncology, M.D. Anderson Cancer Center, Houston, TX
6/2002-5/2005 Clinical Residency, University of North Carolina, Chapel Hill, NC

Board Certifications

11/2011 ABIM Medical Oncology
8/2005 ABIM Internal Medicine

Experience/Service

Academic Appointments

Instructor, Department of Lymphoma/Myeloma - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2011-6/2012
Instructor, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2006-6/2008
Assistant Professor, Division of Internal Medicine, The University of North Carolina, Chapel Hill, NC, 6/2005-9/2006

Administrative Appointments/Responsibilities

Hematology Grand Rounds, Lymphoma Chair, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/2013-present
Co-Director Lymphoma Planning Clinic, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 8/2013-present

Other Appointments/Responsibilities

Chair, Diffuse Large B Cell Lymphoma Translational Biology Program, Houston, TX, 5/2013-present

Institutional Committee Activities

Senator, MD Anderson Faculty Senate, 9/2013-present
Faculty Lead, eResearch Design Project Implementation Team, 9/2013-10/2013
Chair, Lymphoma Informatics Committee, 4/2013-present
Member, New Drug Development Team, MD Anderson Cancer Center Lymphoma Department, 1/2013-present
Member, DLBCL Clinical Trial Team, MD Anderson Cancer Center Lymphoma Department, 7/2010-present

Honors and Awards

2015-present 2015 Career Development Award from Conquer Cancer Foundation, ASCO
2015-present Lymphoma Clinical Research Mentoring Program, Lymphoma Research Foundation
2014-present R. Lee Clark Fellow, MD Anderson Cancer Center
2012-2013 American Society of Clinical Oncology Young Investigator Award
2011 American Society of Hematology Clinical Research Training Institute
2011 Conquer Cancer Foundation of ASCO Oncology Trainee Travel Award
2010-present Paul Calabresi Career Development Award in Clinical Oncology, M.D. Anderson Cancer Center
2010 Janice Davis Singletary Fellowship for Lymphoma, M.D. Anderson Cancer Center
2009 American Society of Hematology Travel Award
2003 Intern of the Year Award
2002 Alpha Omega Alpha Medical Honor Society
2002 Equal Access Homeless Clinic Award, University of Florida College of Medicine

Professional Memberships

American Association for Cancer Research
Associate Member, 1/2010-present
American Society of Clinical Oncology
Associate Member, 1/2009-present
American Society of Hematology
Associate Member, 1/2009-present
Association for Patient Oriented Research
Member, 1/2010-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Westin JR. Busting Robustness: Using Cancer's Greatest Strength to Our Advantage. Future Oncology, January 2015. In Press. PMID: 24673642.
2. Pinnix CC, Smith GL, Milgrom S, Osborne EM, Reddy JP, Akhtari M, Reed V, Arzu I, Allen PK, Wogan CF, Fanale MA, Oki Y, Turturro F, Romaguera J, Fayad L, Fowler N, Westin J, Nastoupil L, Hagemeister FB, Rodriguez MA, Ahmed S, Nieto Y, Dabaja B. Predictors of Radiation Pneumonitis in Patients Receiving Intensity Modulated Radiation Therapy for Hodgkin and Non-Hodgkin Lymphoma. Int J Radiat Oncol Biol Phys 92(1):175-182, 5/2015. PMID: 25863764.
3. Pinnix CC, Dabaja B, Ahmed MA, Chuang HH, Costelloe C, Wogan CF, Reed V, Romaguera JE, Neelapu S, Oki Y, Rodriguez MA, Fayad L, Hagemeister FB, Nastoupil L, Turturro F, Fowler N, Fanale MA, Nieto Y, Khouri IF, Ahmed S, Medeiros LJ, Davis RE, Westin J. Single-Institution Experience in the Treatment of Primary Mediastinal B Cell Lymphoma Treated With Immunochemotherapy in the Setting of Response Assessment by (18)Fluorodeoxyglucose Positron Emission Tomography. Int J Radiat Oncol Biol Phys 92(1):113-121, 5/2015. PMID: 25863759.
4. Tao R, Allen PK, Rodriguez A, Shihadeh F, Pinnix CC, Arzu I, Reed VK, Oki Y, Westin JR, Fayad LE, Medeiros LJ, Dabaja B. Benefit of Consolidative Radiation Therapy for Primary Bone Diffuse Large B-Cell Lymphoma. Int J Radiat Oncol Biol Phys. e-Pub 3/2015. PMID: 25754633.
5. Oki Y, Younes A, Knicerkbocker J, Samaniego F, Nastoupil L, Hagemeister F, Romaguera J, Fowler N, Kwak L, Westin J. Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma. Haematologica. e-Pub 3/2015. PMID: 25820332.
6. Bui PL, Vicens RA, Westin JR, Jensen CT. Multimodality imaging of Epstein-Barr virus-associated inflammatory pseudotumor-like follicular dendritic cell tumor of the spleen: case report and literature review. Clin Imaging. e-Pub 1/2015. PMID: 25725946.
7. Cheah CY, Oki Y, Westin JR, Turturro F. A clinician's guide to double hit lymphomas. Br J Haematol 168(6). e-Pub 12/2014. PMID: 25529575.
8. Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 15(12):1311-8, 11/2014. e-Pub 10/2014. PMID: 25439689.
9. Westin JR, McLaughlin P, Romaguera J, Hagemeister FB, Pro B, Dang NH, Samaniego F, Rodriguez MA, Fayad L, Oki Y, Fanale M, Fowler N, Nastoupil L, Feng L, Loyer E, Younes A. Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol 167(2):177-84, 10/2014. e-Pub 7/2014. PMID: 25039868.
10. Westin JR. Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma. Clin Lymphoma Myeloma Leuk 14(5):335-342, 10/2014. e-Pub 2/2014. PMCID: PMC4125533.
11. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR. Double Hit Lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol 166(6):891-901, 9/2014. e-Pub 6/2014. PMID: 24943107.
12. Younes A, Thieblemont C, Morschhauser F, Flinn I, Friedberg JW, Amorim S, Hivert B, Westin J, Vermeulen J, Bandyopadhyay N, de Vries R, Balasubramanian S, Hellemans P, Smit JW, Fourneau N, Oki Y. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol 15(9):1019-26, 8/2014. e-Pub 7/2014. PMID: 25042202.
13. Cai Q, Westin J, Fu K, Desai M, Zhang L, Huang H, Jiang W, Liang R, Qian Z, Champlin RE, Wang M. Accelerated Therapeutic Progress in Diffuse Large B-cell Lymphoma. Ann Hematol 93(4):541-56, 4/2014. e-Pub 12/2013. PMID: 24375125.
14. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 15(1):69-77, 1/2014. e-Pub 12/2013. PMCID: PMC3922714.
15. Sasaki K, Pemmaraju N, Westin JR, Wang WL, Khoury JD, Podoloff DA, Moon B, Daver N, Borthakur G. A single case of rosai-dorfman disease marked by pathologic fractures, kidney failure, and liver cirrhosis treated with single-agent cladribine. Front Oncol 4:297, 2014. e-Pub 10/2014. PMCID: PMC4212618.
16. Dabaja BS, Phan J, Mawlawi O, Medeiros LJ, Etzel C, Liang FW, Podoloff D, Oki Y, Hagemeister FB, Chuang H, Fayad LE, Westin JR, Shihadeh F, Allen PK, Wogan CF, Rodriguez MA. Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma. Leuk Lymphoma 54(12):2631-8, 12/2013. e-Pub 5/2013. PMCID: PMC3827734.
17. Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol 163(5):611-20, 12/2013. e-Pub 10/2013. PMID: 24117234.
18. Westin JR, Thompson MA, Cataldo VD, Fayad LE, Fowler N, Fanale MA, Neelapu S, Samaniego F, Romaguera J, Shah J, McLaughlin P, Pro B, Kwak LW, Sanjorjo P, Murphy WA, Jimenez C, Toth B, Dong W, Hagemeister FB. Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial. Clin Lymphoma Myeloma Leuk 13(2):99-105, 4/2013. e-Pub 12/2012. PMCID: PMC3881262.
19. Westin JR, Kurzrock R. It's About Time: Lessons for Solid Tumors from Chronic Myelogenous Leukemia Therapy. Mol Cancer Ther 11(12):2549-55, 12/2012. e-Pub 11/2012. PMID: 23204432.
20. Westin JR, Gibbs A, Mills KR, Neelapu SS. Hodgkin lymphoma untreated for six years presenting with tracheoesophageal fistula. Case Report Med 2012:457908, 2012. e-Pub 7/2012. PMCID: PMC3395413.
21. Westin JR, Neelapu SS. Therapy of newly diagnosed follicular lymphoma. Front Oncol 2:188, 2012. e-Pub 12/2012. PMID: 23248775.
22. Davis RE, Westin JR. Vive la resistance: stem cells in mantle cell lymphoma. Leuk Lymphoma 52(6):944-5, 6/2011. e-Pub 4/2011. PMID: 21463111.
23. Westin JR, Saliba RM, De Lima M, Alousi A, Hosing C, Qazilbash MH, Khouri IF, Shpall EJ, Anderlini P, Rondon G, Andersson BS, Champlin R, Couriel DR. Steroid-Refractory Acute GVHD: Predictors and Outcomes. Adv Hematol 2011:601953, 2011. e-Pub 11/2011. PMCID: PMC3216266.
24. Westin J, McLaughlin P. De novo CD5+ diffuse large B-cell lymphoma: a distinct subset with adverse features, poor failure-free survival and outcome with conventional therapy. Leuk Lymphoma 51(1):161-3, 1/2010. PMID: 19863175.
25. Westin JR, Fayad LE. Beyond R-CHOP and the IPI in large-cell lymphoma: molecular markers as an opportunity for stratification. Curr Hematol Malig Rep 4(4):218-24, 10/2009. PMID: 20425411.

Editorials

1. Westin JR. Busting robustness: using cancer's greatest strength to our advantage. Future Oncol. e-Pub 3/2014. PMID: 24673642.
2. Westin J, Hagemeister F. R-CHOP every 21 days for diffuse large B-cell lymphoma: still the standard of care? J Comp Eff Res 2(6):537-40, 11/2013. PMID: 24236792.

Abstracts

1. Fayad L, Rodriguez A, Samaniego F, Fowler N, Oki Y, Turturro F, Westin J, Kwak L, Sabaja B, Feng L, Davis RE, Neelapu S. Antibiotic Therapy of H. Pylori negative Gastric MALT Lymphoma. Blood (ASH Annual Meeting Abstracts 2014) 124(21), 12/2014.
2. Hagemeister F, Westin J, Fayad L, Samaniego F, Turturro F, Chen W, Zhang L, Badillo M. Ibrutinib and Rituximab are an Efficacious and Safe Combination in Relapsed Mantel Cell Lymphoma: Preliminary Results from a Phase II Clinical Trial. Blood (ASH Annual Meeting Abstracts 2014) 124(21), 12/2014.
3. Ahmed S, Ciurea SO, Fayad L, Oran B, Parmar S, Popat U, Westin J, Turturro F, Medeiros LJ, Gulbis AM, Young KH. Outcomes Following Allogenic Stem Cell Transplantation (AlloSCT) in Patients with Primary Mediastinal (PMBL) Germinal Center B (GCB) and Non-GCB Cell-like Diffuse Large B-Cell Lymphomas (DLBCL). Blood (ASH Annual Meeting Abstracts 2014) 124(21), 12/2014.
4. Rodriguez A, Samaniego F, Fanale M, Wang M, Oki Y, Turturro F, Westin J, Nastoupil L, Kwak L, David RE, Neelapu S. R-Bendamustine vs. R-CHOP as Initial Treatment for Advanced Stage Low Grade Follicular Lymphoma: A Matched-Pair Analysis. Blood (ASH Annual Meeting Abstracts 2014) 124(21), 12/2014.
5. Xu J, David RE, Zhiqiang Wang, Westin J. Selinexor (KPT-330) is Not Cross-Resistant with Chemotherapy and Demonstrates Strong Synergy with Targeted Therapy in DLBCL. Blood (ASH Annual Meeting Abstracts 2014) 124(21), 12/2014.
6. Rodriguez A, Samaniego F, Fanale M, Wang M, Oki Y, Turturro F, Westin J, Kwak L, Nastoupil L, Cheah C, Feng L, Rohren E. SUVmax on Pre-Treatment FDG PET Scan is Not Predictive of Outcome in Follicular Lymphoma after R-CHOP Therapy. Blood (ASH Annual Meeting Abstracts 2014) 124(21), December 6, 2014, 12/2014.
7. Nastoupil LJ, Neelapu SS, Samaniego F, Hagemeister FB, Romaguera JR, Kwak LW, Wang M, Fayad L, Fanale MA, Oki Y, Westin JR, Rodriguez MA, Cabanillas F, McLaughlin P, Fowler NH. 10-year remission rates following rituximab (R) and FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) with interferon (IFN) maintenance in indolent lymphoma: Results of a randomized study. J Clin Oncol 32:5s,((suppl; abstr 8528)). e-Pub 6/2014.
8. Janku F, Oki Y, Falchook GS, Subbiah V, Naing A, Bravo VMV, Hong DS, Westin JR, Nunez C, Fayad L, Neelapu SS, Kwak LW, Shpall EJ, Wheler JJ, Barnes T, Liang WS, Salhia B, Meric-Bernstam F. Activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated refractory Hodgkin lymphoma patients. J Clin Oncol 32:5s, 2014. e-Pub 6/2014.
9. Ahmed MA, Barac R, Medeiros LJ, Ma L, Fayad L, Romaguera JE, Oki Y, Rodriguez MA, Pinnix C, Kwak LW, Hagemeister FB, Davis RE, Westin JR. Treatment outcomes and prognostic factors for primary mediastinal B-cell lymphoma: The MD Anderson experience. J Clin Oncol 32:5s. e-Pub 6/2014.
10. Fanale MA, Westin JR, Fowler N, Neelapu SS, Hagemeister FB, Rodriguez MA, Younes A. A Phase I Study Of Panobinostat In Combination With ICE (Ifosfamide, Carboplatin and Etoposide) In Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma (cHL). Blood (ASH Annual Meeting Abstracts) 122(21):252, 12/2013.
11. Flinn I, Berdeja J, Friedberg JW, Casulo C, Thieblemont C, Morschhauser F, Westin JR, Seetharam S, Hellemans P, Smit H, de Vries R, Dauphinee E, Badamo-Dotzis J, Fourneau N, Oki Y. Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP): Updated Results From a Phase 1b Study in Patients With CD20-Positive B-Cell non-Hodgkin’s lymphoma (NHL). Blood (ASH Annual Meeting Abstracts) 2013 122(21):852, 12/2013.
12. Noorani M, Davis RE, Neelapu SS, Rodriguez A, Hagemeister FB, Fowler N, Wang M, Fanale MA, Samaniego F, Dabaja BS, Pinnix C, Kwak LW, Romaguera JE, Khouri I, Westin JR, Fayad LE. Double Hit Lymphoma: M.D. Anderson Experience Submitted. Blood (ASH Annual Meeting Abstracts) 2013 122(21):1776, 12/2013.
13. Jason R. Westin, Min Zhang, Seema Rawal, Larry W. Kwak, Sattva S. Neelapu, and R. Eric Davis. Integrated Analysis Of Genomic and Gene Expression Profiles In Follicular Lymphoma Reveals Subsets and Driver Genes Of Potential Microenvironmental Importance. Blood (ASH Annual Meeting Abstracts) 2013 122(21):2487, 12/2013.
14. Romaguera JE, Kwak LW, Hagemeister FB, Rodriguez MA, Oki Y, Westin JR, Turturro F, Overman MJ, Neelapu SS, Fowler N, Fayad LE. Long-Term Remissions of Patients with Follicular Lymphoma Grade 3 Treated with Rituximab, Cyclophospamide, Doxorubicine, Vincristine and Prednisone (R-CHOP). Blood (ASH Annual Meeting Abstracts) 2013 122(21):3028, 12/2013.
15. Saliba RM, Xu-Monette ZY, Rondon G, Valverde R, Korbling M, Gulbis AM, Anderlini P, Sairah A, Hosing CM, Popat UR, Kebriaei P, Fayad LE, Westin JR, Turturro F, Medeiros LJ, Champlin RE, Young KH. Outcomes following Autologous Stem Cell Transplantation (ASCT) in in Patients with Germinal Center B (GCB) and non-GCB Cell-Like Diffuse Large B cell Lymphomas (DLBCL) According to Conditioning with BEAM-Rituximab (Standard vs. High-Dose) vs. BEAM/Yttrium-90 Ibritumomab Tiuxetan (90YIT). Blood (ASH Annual Meeting Abstracts) 2013 122(21):3350, 12/2013.
16. Garrido-Laguna I, Velez-Bravo V, Falchook GS, Subbiah V, Hong DS, Oki Y, Westin JR, Nunez CA, Fayad LE, Kwak LW, Shpall EJ, Wheler JJ, Liang W, Salhia B, Meric-Bernstam F, Kurzrock R, Fanale MA. Significant activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated refractory Hodgkin lymphoma patients. Blood (ASH Annual Meeting Abstracts) 2013 122(21):3048, 12/2013.
17. Westin J., Chu F., Fayad L, Kwak LW, Fowler NH, Romaguera J., Hagemeister FB, Fanale M, Samaniego F, Allen R, Feng L, Baladandayuthapani V, Rotem-Yehudar R, and Neelapu SS. Final Update of Phase II Safety and Efficacy Study of CT-011, a Humanized anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma. Hematological Oncology Volume 31(Issue S1), 6/2013.
18. Chu F., Westin J., Zhang M, Feng L, Baladandayuthapani V, Wang Z., Allen R, Wallace M., Vence LM, Radvanyi L, Kwak LW, Rotem-Yehudar R, Davis RE, and Neelapu SS. Immunological Effects and Predictive Gene Signatures in Patients with Relapsed Follicular Lymphoma treated with CT-011, a Humanized anti-PD-1 Monoclonal. Blood (ASH Annual Meeting Abstracts) 120:Abstract 162, 2012.
19. Westin J., Chu F., Fayad L, Kwak LW, Fowler NH, Romaguera J., Hagemeister FB, Fanale M, Samaniego F, Allen R, Feng L, Baladandayuthapani V, Rotem-Yehudar R, and Neelapu SS. Phase II Safety and Efficacy Study of CT-011, a Humanized anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma. Blood (ASH Annual Meeting Abstracts) 120:Abstract 793, 2012.
20. Oki Y., Westin J., Fowler N, Neelapu S, McLaughlin P, Kwak LW, Romaguera J, Fanale M, Rodriguez MA, Orlowski RZ, Wang M, Ouzanian S. R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL. Blood (ASH Annual Meeting Abstracts) 12:Abstract 3707, 2012.
21. Westin J., Fu S., Hong D., Helgason T., Culotta C., Angelo L., Ouyang F., Westin S., Kurzrock R. Validation of the Phase 0 Concept. J Clin Oncol 29:(suppl; abstr TPS143), 2011.
22. Westin J., Thompson M., Cataldo V, Toth B, Sanjorjo P, Bourgeois S, Jimenez C, Murphy W, Fanale M, Fayad L, Fowler N, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez A, Shah J, Hagemeister F. Bone Loss in Lymphoma Patients Prior to Receiving Frontline Therapy. Presented at the 2010 14th Annual International Congress on Hematologic Malignancies, 2010.
23. Westin J., Chu F., Foglietta,M., Rodionov G., Rotem-Yehudar R., Neelapu SS. Phase II safety and efficacy study of CT-011, a humanized anti-PD-1 monoclonal antibody, in combination with rituximab in patients with relapsed follicular lymphoma. J Clin Oncol 28(15_suppl TPS305), 2010.
24. Westin J., Thompson M., Cataldo V, Toth B, Sanjorjo P, Bourgeois S, Jimenez C, Murphy W, Fanale M, Fayad L, Fowler N, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez A, Shah J, Hagemeister F. The effect of zoledronic acid on the prevention of bone loss in lymphoma patients receiving first-line therapy. J Clin Oncol 28(no. 15_suppl 9103), 2010.
25. Westin J., Thompson M., Cataldo V, Toth B, Sanjorjo P, Bourgeois S, Jimenez C, Murphy W, Fanale M, Fayad L, Fowler N, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez A, Shah J, Hagemeister F. Zoledronic acid treatment of frontline lymphoma patients; Prevention of bone loss. Poster presentation at the Hematologic Malignancies 2010 - Sixth International Conference, 2010.
26. Westin J., Thompson M., Cataldo V, Toth B, Sanjorjo P, Bourgeois S, Jimenez C, Murphy W, Fanale M, Fayad L, Fowler N, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez A, Shah J, Hagemeister F. Bone Loss in Lymphoma Patients Receiving Frontline Therapy: Urine NTx and Bone Specific Alkaline Phosphatase Provide Early Evidence of Zoledronic Acid Response. Blood (ASH Annual Meeting Abstracts) 114:Abstract 3922, 2009.
27. Westin J., Thompson M., Cataldo V, Toth B, Sanjorjo P, Bourgeois S, Jimenez C, Murphy W, Fanale M, Fayad L, Fowler N, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez A, Shah J, Hagemeister F. The Effect of Zoledronic Acid on the Prevention of Bone Loss in Lymphoma Patients Receiving First-line Therapy. Clin Lymphoma Myeloma 9((6)):E30, 2009.
28. Westin J., Saliba R., de Lima M, Alousi A., Hosing C., Qazilbash M, Khouri I., Shpall E., Champlin R. Couriel, D. Risk Factors for Response after Initial Therapy for Acute Graft-Versus-Host-Disease (aGVHD). Blood (ASH Annual Meeting Abstracts) 110:Abstract 5015, 2007.

Book Chapters

1. Liu, X, Westin J. "Targeted Therapy of Lymphomas". In: Handbook of Targeted Cancer Therapy, 1st. Ed(s) Karp D, Flachook G. Lippincott Williams & Wilkins, 2014. ISBN: 9781451193268.
2. Westin J, Kantarjian H, Kurzrock R. "Treatment of Chronic Myelogenous Leukemia as a Paradigm for Solid Tumors: How Targeted Agents in Newly Diagnosed Disease Transformed Outcomes". In: 2012 ASCO Educational Book, ASCO Annual Meeting, 2012.
3. Westin J, Romaguera J. "Multidisciplinary Approach to Cancer: A Medical Oncologists View.". In: Oncologic Imaging for the Practicing Radiologist, Medical Oncologist and Surgeon, 2010.
4. Westin J, Hagemeister R, Fanale M. "Hodgkin Lymphoma". In: The MD Anderson Manual of Medical Oncology. Second edition, 2009.

Letters to the Editor

1. Thompson MA, Westin JR, Hagemeister FB. BMD Screening should be routine in lymphoma-Response to Paccou et al. Annals of Oncology. In Press.
2. Thompson MA, Westin JR, Hagemeister FB. Bone mineral density screening should be routine in lymphoma patients. Ann Oncol 25(4):913-4, 4/2014. PMID: 24667725.
3. Westin J, Oki Y, Fayad L. Could treatment with R-HCVAD/R-MA as compared to R- CHOP truly result in improved outcomes for patients with high-risk diffuse large B cell lymphoma? - Response to Landsburg et al. Br J Haematol 165(1):146-7, 4/2014. e-Pub 12/2013. PMID: 24329994.

Grant & Contract Support

Title: Conquer Foundation Career Investigator Award
Funding Source: American Society of Clinical Oncology (ASCO)
Role: Project Leader
Principal Investigator: Jason Westin, M.D.
Duration: 7/1/2015 - 6/30/2018
 
Title: B-Cell Lymphoma Moon Shot-Developing Minimal Resideual Disease Assays
Funding Source: M.D. Anderson Cancer Center
Role: Project Leader
Duration: 9/1/2014 - present
 
Title: R. Lee Clark Fellow Award Development of Therapeutically Relevant Biomarkers in Relapsed Diffuse Large B Cell Lymphoma
Funding Source: MD Anderson Cancer Center
Role: Principal Investigator
Duration: 4/2014 - present
 
Title: ASCO YIA Targeting Chemotherapy Resistance in Diffuse Large B-Cell Lymphoma: Defining the Role of the PI3K/Akt/mTOR Pathway
Funding Source: American Society of Clinical Oncology (ASCO)
Role: Principal Investigator
Duration: 7/1/2012 - 12/2013
 
Title: Developing Combination Chemotherapy and Targeting Resistance in B-Cell Lymphoma
Funding Source: Southwest Oncology Group
Role: Co-Principal Investigator
Principal Investigator: R. Eric Davis
Duration: 8/15/2011 - 4/2014
 
Title: Paul Calabresi K12 Career Development Award in Clinical Oncology
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Duration: 9/20/2010 - 9/19/2013
 
Title: Loan Repayment Clinical Research - Extramural
Funding Source: NIH/NCI
Role: Co-Principal Investigator

Last updated: 8/14/2015